Global Sickle Cell Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Sickle Cell Disease Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Sickle Cell Disease Drug include Global Blood Therapeutics Inc, Gilead Sciences Inc, Genethon SA, Gamida Cell Ltd, Errant Gene Therapeutics LLC, Editas Medicine Inc, Daiichi Sankyo Co Ltd, CSL Ltd and CRISPR Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Sickle Cell Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Sickle Cell Disease Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Sickle Cell Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sickle Cell Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Sickle Cell Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Sickle Cell Disease Drug sales, projected growth trends, production technology, application and end-user industry.
Sickle Cell Disease Drug Segment by Company
Global Blood Therapeutics Inc
Gilead Sciences Inc
Genethon SA
Gamida Cell Ltd
Errant Gene Therapeutics LLC
Editas Medicine Inc
Daiichi Sankyo Co Ltd
CSL Ltd
CRISPR Therapeutics
Calimmune Inc
Bristol-Myers Squibb Co
bluebird bio Inc
Bioverativ Inc
Bio Products Laboratory Ltd
ArQule Inc
Annexin Pharmaceuticals AB
Angiocrine Bioscience Inc
Addmedica SAS
Acceleron Pharma Inc
Sickle Cell Disease Drug Segment by Type
CAL-H
DRX-194
CTX-001
BIVV-003
ARQ-092
Others
Sickle Cell Disease Drug Segment by Application
Hospital
Clinic
Others
Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Sickle Cell Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Sickle Cell Disease Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Sickle Cell Disease Drug include Global Blood Therapeutics Inc, Gilead Sciences Inc, Genethon SA, Gamida Cell Ltd, Errant Gene Therapeutics LLC, Editas Medicine Inc, Daiichi Sankyo Co Ltd, CSL Ltd and CRISPR Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Sickle Cell Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Sickle Cell Disease Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Sickle Cell Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sickle Cell Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Sickle Cell Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Sickle Cell Disease Drug sales, projected growth trends, production technology, application and end-user industry.
Sickle Cell Disease Drug Segment by Company
Global Blood Therapeutics Inc
Gilead Sciences Inc
Genethon SA
Gamida Cell Ltd
Errant Gene Therapeutics LLC
Editas Medicine Inc
Daiichi Sankyo Co Ltd
CSL Ltd
CRISPR Therapeutics
Calimmune Inc
Bristol-Myers Squibb Co
bluebird bio Inc
Bioverativ Inc
Bio Products Laboratory Ltd
ArQule Inc
Annexin Pharmaceuticals AB
Angiocrine Bioscience Inc
Addmedica SAS
Acceleron Pharma Inc
Sickle Cell Disease Drug Segment by Type
CAL-H
DRX-194
CTX-001
BIVV-003
ARQ-092
Others
Sickle Cell Disease Drug Segment by Application
Hospital
Clinic
Others
Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Sickle Cell Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Sickle Cell Disease Drug Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Sickle Cell Disease Drug Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Sickle Cell Disease Drug Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Sickle Cell Disease Drug Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Sickle Cell Disease Drug Market Dynamics
- 2.1 Sickle Cell Disease Drug Industry Trends
- 2.2 Sickle Cell Disease Drug Industry Drivers
- 2.3 Sickle Cell Disease Drug Industry Opportunities and Challenges
- 2.4 Sickle Cell Disease Drug Industry Restraints
- 3 Sickle Cell Disease Drug Market by Manufacturers
- 3.1 Global Sickle Cell Disease Drug Revenue by Manufacturers (2020-2025)
- 3.2 Global Sickle Cell Disease Drug Sales by Manufacturers (2020-2025)
- 3.3 Global Sickle Cell Disease Drug Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Sickle Cell Disease Drug Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Sickle Cell Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Sickle Cell Disease Drug Manufacturers, Product Type & Application
- 3.7 Global Sickle Cell Disease Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Sickle Cell Disease Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Sickle Cell Disease Drug Players Market Share by Revenue in 2024
- 3.8.3 2024 Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3
- 4 Sickle Cell Disease Drug Market by Type
- 4.1 Sickle Cell Disease Drug Type Introduction
- 4.1.1 CAL-H
- 4.1.2 DRX-194
- 4.1.3 CTX-001
- 4.1.4 BIVV-003
- 4.1.5 ARQ-092
- 4.1.6 Others
- 4.2 Global Sickle Cell Disease Drug Sales by Type
- 4.2.1 Global Sickle Cell Disease Drug Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Sickle Cell Disease Drug Sales by Type (2020-2031)
- 4.2.3 Global Sickle Cell Disease Drug Sales Market Share by Type (2020-2031)
- 4.3 Global Sickle Cell Disease Drug Revenue by Type
- 4.3.1 Global Sickle Cell Disease Drug Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Sickle Cell Disease Drug Revenue by Type (2020-2031)
- 4.3.3 Global Sickle Cell Disease Drug Revenue Market Share by Type (2020-2031)
- 5 Sickle Cell Disease Drug Market by Application
- 5.1 Sickle Cell Disease Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Sickle Cell Disease Drug Sales by Application
- 5.2.1 Global Sickle Cell Disease Drug Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Sickle Cell Disease Drug Sales by Application (2020-2031)
- 5.2.3 Global Sickle Cell Disease Drug Sales Market Share by Application (2020-2031)
- 5.3 Global Sickle Cell Disease Drug Revenue by Application
- 5.3.1 Global Sickle Cell Disease Drug Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Sickle Cell Disease Drug Revenue by Application (2020-2031)
- 5.3.3 Global Sickle Cell Disease Drug Revenue Market Share by Application (2020-2031)
- 6 Global Sickle Cell Disease Drug Sales by Region
- 6.1 Global Sickle Cell Disease Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Sickle Cell Disease Drug Sales by Region (2020-2031)
- 6.2.1 Global Sickle Cell Disease Drug Sales by Region (2020-2025)
- 6.2.2 Global Sickle Cell Disease Drug Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Sickle Cell Disease Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Sickle Cell Disease Drug Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Sickle Cell Disease Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Sickle Cell Disease Drug Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Sickle Cell Disease Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Sickle Cell Disease Drug Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Sickle Cell Disease Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Sickle Cell Disease Drug Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Sickle Cell Disease Drug Revenue by Region
- 7.1 Global Sickle Cell Disease Drug Revenue by Region
- 7.1.1 Global Sickle Cell Disease Drug Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Sickle Cell Disease Drug Revenue by Region (2020-2025)
- 7.1.3 Global Sickle Cell Disease Drug Revenue by Region (2026-2031)
- 7.1.4 Global Sickle Cell Disease Drug Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Sickle Cell Disease Drug Revenue (2020-2031)
- 7.2.2 North America Sickle Cell Disease Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Sickle Cell Disease Drug Revenue (2020-2031)
- 7.3.2 Europe Sickle Cell Disease Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Sickle Cell Disease Drug Revenue (2020-2031)
- 7.4.2 Asia-Pacific Sickle Cell Disease Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Sickle Cell Disease Drug Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Sickle Cell Disease Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Global Blood Therapeutics Inc
- 8.1.1 Global Blood Therapeutics Inc Comapny Information
- 8.1.2 Global Blood Therapeutics Inc Business Overview
- 8.1.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
- 8.1.5 Global Blood Therapeutics Inc Recent Developments
- 8.2 Gilead Sciences Inc
- 8.2.1 Gilead Sciences Inc Comapny Information
- 8.2.2 Gilead Sciences Inc Business Overview
- 8.2.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
- 8.2.5 Gilead Sciences Inc Recent Developments
- 8.3 Genethon SA
- 8.3.1 Genethon SA Comapny Information
- 8.3.2 Genethon SA Business Overview
- 8.3.3 Genethon SA Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Genethon SA Sickle Cell Disease Drug Product Portfolio
- 8.3.5 Genethon SA Recent Developments
- 8.4 Gamida Cell Ltd
- 8.4.1 Gamida Cell Ltd Comapny Information
- 8.4.2 Gamida Cell Ltd Business Overview
- 8.4.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
- 8.4.5 Gamida Cell Ltd Recent Developments
- 8.5 Errant Gene Therapeutics LLC
- 8.5.1 Errant Gene Therapeutics LLC Comapny Information
- 8.5.2 Errant Gene Therapeutics LLC Business Overview
- 8.5.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
- 8.5.5 Errant Gene Therapeutics LLC Recent Developments
- 8.6 Editas Medicine Inc
- 8.6.1 Editas Medicine Inc Comapny Information
- 8.6.2 Editas Medicine Inc Business Overview
- 8.6.3 Editas Medicine Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
- 8.6.5 Editas Medicine Inc Recent Developments
- 8.7 Daiichi Sankyo Co Ltd
- 8.7.1 Daiichi Sankyo Co Ltd Comapny Information
- 8.7.2 Daiichi Sankyo Co Ltd Business Overview
- 8.7.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
- 8.7.5 Daiichi Sankyo Co Ltd Recent Developments
- 8.8 CSL Ltd
- 8.8.1 CSL Ltd Comapny Information
- 8.8.2 CSL Ltd Business Overview
- 8.8.3 CSL Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 CSL Ltd Sickle Cell Disease Drug Product Portfolio
- 8.8.5 CSL Ltd Recent Developments
- 8.9 CRISPR Therapeutics
- 8.9.1 CRISPR Therapeutics Comapny Information
- 8.9.2 CRISPR Therapeutics Business Overview
- 8.9.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
- 8.9.5 CRISPR Therapeutics Recent Developments
- 8.10 Calimmune Inc
- 8.10.1 Calimmune Inc Comapny Information
- 8.10.2 Calimmune Inc Business Overview
- 8.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Calimmune Inc Sickle Cell Disease Drug Product Portfolio
- 8.10.5 Calimmune Inc Recent Developments
- 8.11 Bristol-Myers Squibb Co
- 8.11.1 Bristol-Myers Squibb Co Comapny Information
- 8.11.2 Bristol-Myers Squibb Co Business Overview
- 8.11.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
- 8.11.5 Bristol-Myers Squibb Co Recent Developments
- 8.12 bluebird bio Inc
- 8.12.1 bluebird bio Inc Comapny Information
- 8.12.2 bluebird bio Inc Business Overview
- 8.12.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
- 8.12.5 bluebird bio Inc Recent Developments
- 8.13 Bioverativ Inc
- 8.13.1 Bioverativ Inc Comapny Information
- 8.13.2 Bioverativ Inc Business Overview
- 8.13.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
- 8.13.5 Bioverativ Inc Recent Developments
- 8.14 Bio Products Laboratory Ltd
- 8.14.1 Bio Products Laboratory Ltd Comapny Information
- 8.14.2 Bio Products Laboratory Ltd Business Overview
- 8.14.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
- 8.14.5 Bio Products Laboratory Ltd Recent Developments
- 8.15 ArQule Inc
- 8.15.1 ArQule Inc Comapny Information
- 8.15.2 ArQule Inc Business Overview
- 8.15.3 ArQule Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 ArQule Inc Sickle Cell Disease Drug Product Portfolio
- 8.15.5 ArQule Inc Recent Developments
- 8.16 Annexin Pharmaceuticals AB
- 8.16.1 Annexin Pharmaceuticals AB Comapny Information
- 8.16.2 Annexin Pharmaceuticals AB Business Overview
- 8.16.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.16.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
- 8.16.5 Annexin Pharmaceuticals AB Recent Developments
- 8.17 Angiocrine Bioscience Inc
- 8.17.1 Angiocrine Bioscience Inc Comapny Information
- 8.17.2 Angiocrine Bioscience Inc Business Overview
- 8.17.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.17.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
- 8.17.5 Angiocrine Bioscience Inc Recent Developments
- 8.18 Addmedica SAS
- 8.18.1 Addmedica SAS Comapny Information
- 8.18.2 Addmedica SAS Business Overview
- 8.18.3 Addmedica SAS Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.18.4 Addmedica SAS Sickle Cell Disease Drug Product Portfolio
- 8.18.5 Addmedica SAS Recent Developments
- 8.19 Acceleron Pharma Inc
- 8.19.1 Acceleron Pharma Inc Comapny Information
- 8.19.2 Acceleron Pharma Inc Business Overview
- 8.19.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.19.4 Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
- 8.19.5 Acceleron Pharma Inc Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Sickle Cell Disease Drug Value Chain Analysis
- 9.1.1 Sickle Cell Disease Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Sickle Cell Disease Drug Production Mode & Process
- 9.2 Sickle Cell Disease Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Sickle Cell Disease Drug Distributors
- 9.2.3 Sickle Cell Disease Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
